产品
编 号：F762751
分子式：C28H30N4O2
分子量：454.56
分子式：C28H30N4O2
分子量：454.56
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2980758-31-2
产品详情
生物活性：
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma.
体内研究：
STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity.Animal Model:HepG2 cell xenograft tumor model
Dosage:20, 40 mg/kg, daily for 24 days
Administration:Intraperitoneal injection
Result:Inhibited tumor growth without affecting the body weight.
体外研究：
STAT3-IN-12 (compound 24, 0-10 μM approximately, 72 h) inhibits cancer cell growth and migration in HepG2 and EC109 cells.STAT3-IN-12 (0-20 μM, 16 h) binds to the STAT3 protein and inhibits IL-6-mediated STAT3 phosphorylation, also inhibts STAT3 nuclear localization and dimerization in EC109 and HepG2 cells.STAT3-IN-12 (0-20 μM, 48 h) induces cell apoptosis as well as cycle arrest in HepG2 and EC109 cells.
STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma.
体内研究：
STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity.Animal Model:HepG2 cell xenograft tumor model
Dosage:20, 40 mg/kg, daily for 24 days
Administration:Intraperitoneal injection
Result:Inhibited tumor growth without affecting the body weight.
体外研究：
STAT3-IN-12 (compound 24, 0-10 μM approximately, 72 h) inhibits cancer cell growth and migration in HepG2 and EC109 cells.STAT3-IN-12 (0-20 μM, 16 h) binds to the STAT3 protein and inhibits IL-6-mediated STAT3 phosphorylation, also inhibts STAT3 nuclear localization and dimerization in EC109 and HepG2 cells.STAT3-IN-12 (0-20 μM, 48 h) induces cell apoptosis as well as cycle arrest in HepG2 and EC109 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备